UroGen Pharma Ltd. (URGN) Operating income 2016–2025
UroGen Pharma Ltd. (URGN) annual operating income history from SEC filings — each fiscal year as reported.
-$124.9MFY2025 · since FY2016: $798,000 → -$124.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$124.9M | -29.0% |
| FY2024 | -$96.8M | -47.7% |
| FY2023 | -$65.5M | +17.1% |
| FY2022 | -$79.0M | +14.4% |
| FY2021 | -$92.3M | +27.2% |
| FY2020 | -$126.7M | -15.8% |
| FY2019 | -$109.5M | -41.8% |
| FY2018 | -$77.2M | -286.9% |
| FY2017 | -$19.9M | -2600.0% |
| FY2016 | $798,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Gross marginURGN Operating marginURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →